Literature DB >> 34905501

IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis.

Lucia Longhitano1, Daniele Tibullo1, Nunzio Vicario1, Cesarina Giallongo2, Enrico La Spina3, Alessandra Romano3, Sofia Lombardo4, Marina Moretti5, Francesco Masia5, Anna Rita Daniela Coda6, Santina Venuto6, Paolo Fontana4, Rosalba Parenti1, Giovanni Li Volti1, Michelino Di Rosa1, Giuseppe A Palumbo2, Arcangelo Liso6.   

Abstract

Primary myelofibrosis is a Ph-negative chronic myeloproliferative neoplasm characterized by bone marrow fibrosis and associated with the involvement of several pathways, in addition to bone marrow microenvironment alterations, mostly driven by the activation of the cytokine receptor/JAK2 pathway. Identification of driver mutations has led to the development of targeted therapy for myelofibrosis, contributing to reducing inflammation, although this currently does not translate into bone marrow fibrosis remission. Therefore, understanding the clear molecular cut underlying this pathology is now necessary to improve the clinical outcome of patients. The present study aims to investigate the involvement of IGFBP-6/sonic hedgehog /Toll-like receptor 4 axis in the microenvironment alterations of primary myelofibrosis. We observed a significant increase in IGFBP-6 expression levels in primary myelofibrosis patients, coupled with a reduction to near-normal levels in primary myelofibrosis patients with JAK2V617F mutation. We also found that both IGFBP-6 and purmorphamine, a SHH activator, were able to induce mesenchymal stromal cells differentiation with an up-regulation of cancer-associated fibroblasts markers. Furthermore, TLR4 signaling was also activated after IGFBP-6 and purmorphamine exposure and reverted by cyclopamine exposure, an inhibitor of the SHH pathway, confirming that SHH is involved in TLR4 activation and microenvironment alterations. In conclusion, our results suggest that the IGFBP-6/SHH/TLR4 axis is implicated in alterations of the primary myelofibrosis microenvironment and that IGFBP-6 may play a central role in activating SHH pathway during the fibrotic process.

Entities:  

Keywords:  IGFBP-6; MPNs; TLR4; mesenchymal stem cells; myelofibrosis

Mesh:

Substances:

Year:  2021        PMID: 34905501      PMCID: PMC8714138          DOI: 10.18632/aging.203779

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  65 in total

1.  Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses.

Authors:  Suzanne L Tomchuck; Kevin J Zwezdaryk; Seth B Coffelt; Ruth S Waterman; Elizabeth S Danka; Aline B Scandurro
Journal:  Stem Cells       Date:  2007-10-04       Impact factor: 6.277

Review 2.  Substance p-fibronectin-cytokine interactions in myeloproliferative disorders with bone marrow fibrosis.

Authors:  P Rameshwar; H S Oh; C Yook; P Gascon; V T Chang
Journal:  Acta Haematol       Date:  2003       Impact factor: 2.195

3.  Purmorphamine activates the Hedgehog pathway by targeting Smoothened.

Authors:  Surajit Sinha; James K Chen
Journal:  Nat Chem Biol       Date:  2005-11-20       Impact factor: 15.040

4.  Sex difference in CHI3L1 expression levels in human brain aging and in Alzheimer's disease.

Authors:  Cristina Sanfilippo; Paola Castrogiovanni; Rosa Imbesi; Maria Kazakowa; Giuseppe Musumeci; Kaj Blennow; Henrik Zetterberg; Michelino Di Rosa
Journal:  Brain Res       Date:  2019-06-24       Impact factor: 3.252

5.  Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders.

Authors:  Morten Krogh Jensen; Mads Nikolai Holten-Andersen; Rikke Riisbro; Peter de Nully Brown; Maj Britt Larsen; Lars Kjeldsen; Lene Heickendorff; Nils Brünner; Hans Carl Hasselbalch
Journal:  Eur J Haematol       Date:  2003-11       Impact factor: 2.997

6.  Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice.

Authors:  Hédia Chagraoui; Emiko Komura; Micheline Tulliez; Stéphane Giraudier; William Vainchenker; Françoise Wendling
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113

7.  Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis.

Authors:  Srdan Verstovsek; Taghi Manshouri; Darrell Pilling; Carlos E Bueso-Ramos; Kate J Newberry; Sanja Prijic; Liza Knez; Ksenija Bozinovic; David M Harris; Erika L Spaeth; Sean M Post; Asha S Multani; Raajit K Rampal; Jihae Ahn; Ross L Levine; Chad J Creighton; Hagop M Kantarjian; Zeev Estrov
Journal:  J Exp Med       Date:  2016-08-01       Impact factor: 14.307

8.  Ixazomib Improves Bone Remodeling and Counteracts sonic Hedgehog signaling Inhibition Mediated by Myeloma Cells.

Authors:  Daniele Tibullo; Anna Longo; Nunzio Vicario; Alessandra Romano; Alessandro Barbato; Michelino Di Rosa; Ignazio Barbagallo; Carmelina Daniela Anfuso; Gabriella Lupo; Rosario Gulino; Rosalba Parenti; Giovanni Li Li Volti; Giuseppe Alberto Palumbo; Francesco Di Di Raimondo; Cesarina Giallongo
Journal:  Cancers (Basel)       Date:  2020-01-30       Impact factor: 6.639

9.  Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

Authors:  Hans Michael Kvasnicka; Jürgen Thiele; Carlos E Bueso-Ramos; William Sun; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  J Hematol Oncol       Date:  2018-03-15       Impact factor: 17.388

10.  Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis.

Authors:  Chiara Rossi; Roberta Zini; Sebastiano Rontauroli; Samantha Ruberti; Zelia Prudente; Greta Barbieri; Elisa Bianchi; Simona Salati; Elena Genovese; Niccolò Bartalucci; Paola Guglielmelli; Enrico Tagliafico; Vittorio Rosti; Giovanni Barosi; Alessandro M Vannucchi; Rossella Manfredini
Journal:  Mol Oncol       Date:  2018-11-16       Impact factor: 6.603

View more
  4 in total

1.  Lactate modulates microglia polarization via IGFBP6 expression and remodels tumor microenvironment in glioblastoma.

Authors:  Lucia Longhitano; Nunzio Vicario; Stefano Forte; Cesarina Giallongo; Giuseppe Broggi; Rosario Caltabiano; Giuseppe Maria Vincenzo Barbagallo; Roberto Altieri; Giuseppina Raciti; Michelino Di Rosa; Massimo Caruso; Rosalba Parenti; Arcangelo Liso; Federica Busi; Marco Lolicato; Maria Caterina Mione; Giovanni Li Volti; Daniele Tibullo
Journal:  Cancer Immunol Immunother       Date:  2022-06-03       Impact factor: 6.630

2.  Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.

Authors:  Yinning Xu; Xiaoping Hu; Yiwen Zhang; Zongfu Pan; Zhiyong Sun; Zhongjie Huang; Shuilian Zheng; Hansheng Pan; Xiaozhou Zou; Ping Huang
Journal:  Ann Transl Med       Date:  2022-04

Review 3.  IGFBP-6: At the Crossroads of Immunity, Tissue Repair and Fibrosis.

Authors:  Arcangelo Liso; Santina Venuto; Anna Rita Daniela Coda; Cesarina Giallongo; Giuseppe Alberto Palumbo; Daniele Tibullo
Journal:  Int J Mol Sci       Date:  2022-04-14       Impact factor: 6.208

4.  Neuroprotective Role of α-Lipoic Acid in Iron-Overload-Mediated Toxicity and Inflammation in In Vitro and In Vivo Models.

Authors:  Giuseppe Carota; Alfio Distefano; Mariarita Spampinato; Cesarina Giallongo; Giuseppe Broggi; Lucia Longhitano; Giuseppe A Palumbo; Rosalba Parenti; Rosario Caltabiano; Sebastiano Giallongo; Michelino Di Rosa; Riccardo Polosa; Vincenzo Bramanti; Nunzio Vicario; Giovanni Li Volti; Daniele Tibullo
Journal:  Antioxidants (Basel)       Date:  2022-08-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.